187 related articles for article (PubMed ID: 37931769)
1. Cost-effectiveness of first-line immunotherapy for advanced non-small cell lung cancer with different PD-L1 expression levels: A comprehensive overview.
Wu C; Li W; Tao H; Zhang X; Xin Y; Song R; Wang K; Zuo L; Cai Y; Wu H; Hui W
Crit Rev Oncol Hematol; 2024 Jan; 193():104195. PubMed ID: 37931769
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of first-line immunotherapies for advanced non-small cell lung cancer.
Yang SC; Ou HT; Su WC; Wang SY
Cancer Med; 2023 Apr; 12(7):8838-8850. PubMed ID: 36653947
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitors
Liu S; Dou L; Li S
Therap Adv Gastroenterol; 2024; 17():17562848241233134. PubMed ID: 38425370
[TBL] [Abstract][Full Text] [Related]
4. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
5. Severe immune-related adverse events of immune checkpoint inhibitors for advanced non-small cell lung cancer: a network meta-analysis of randomized clinical trials.
Gu J; Shi L; Jiang X; Wen J; Zheng X; Cai H; Zhang W
Cancer Immunol Immunother; 2022 Sep; 71(9):2239-2254. PubMed ID: 35124713
[TBL] [Abstract][Full Text] [Related]
6. Determining the optimal PD-1/PD-L1 inhibitors for the first-line treatment of non-small-cell lung cancer with high-level PD-L1 expression in China.
Teng MM; Chen SY; Yang B; Wang Y; Han RY; An MN; Dong YL; You HS
Cancer Med; 2021 Sep; 10(18):6344-6353. PubMed ID: 34382361
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review.
Ding H; Xin W; Tong Y; Sun J; Xu G; Ye Z; Rao Y
PLoS One; 2020; 15(9):e0238536. PubMed ID: 32877435
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis.
Siciliano MA; Caridà G; Ciliberto D; d'Apolito M; Pelaia C; Caracciolo D; Riillo C; Correale P; Galvano A; Russo A; Barbieri V; Tassone P; Tagliaferri P
ESMO Open; 2022 Jun; 7(3):100465. PubMed ID: 35427835
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
Dafni U; Tsourti Z; Vervita K; Peters S
Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis.
Li Y; Liang X; Li H; Chen X
Chin Med J (Engl); 2023 Sep; 136(18):2156-2165. PubMed ID: 37596898
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: A sequential model.
Zhao M; Shao T; Chi Z; Tang W
Front Public Health; 2023; 11():1051484. PubMed ID: 36908446
[TBL] [Abstract][Full Text] [Related]
12. Indirect comparison of sintilimab and other PD-L1 inhibitors for first-line treatment of non-squamous non-small-cell lung cancer.
Zhang L; Qian Y; Li J; Cui C; Chen L; Qu S; Lu S
Future Oncol; 2022 May; 18(15):1896-1905. PubMed ID: 35311347
[TBL] [Abstract][Full Text] [Related]
13. Sintilimab plus chemotherapy for first-line treatment of advanced or metastatic nonsquamous non-small-cell lung cancer: network meta-analysis.
Molife C; Brnabic A; Stefaniak VJ; Belger MA; Gruver K; Chen JV; Souri S; Blumenschein GR
Immunotherapy; 2023 Mar; 15(4):293-309. PubMed ID: 36748406
[TBL] [Abstract][Full Text] [Related]
14. The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC.
Aguiar PN; Perry LA; Penny-Dimri J; Babiker H; Tadokoro H; de Mello RA; Lopes GL
Ann Oncol; 2017 Sep; 28(9):2256-2263. PubMed ID: 28633409
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US.
Watson TR; Gao X; Reynolds KL; Kong CY
JAMA Netw Open; 2020 Oct; 3(10):e2016144. PubMed ID: 33052401
[TBL] [Abstract][Full Text] [Related]
16. First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.
Liu Q; Zhou Z; Luo X; Yi L; Peng L; Wan X; Tan C; Zeng X
Front Pharmacol; 2021; 12():788569. PubMed ID: 34992538
[No Abstract] [Full Text] [Related]
17. A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer.
Shao T; Zhao M; Liang L; Tang W
Front Immunol; 2022; 13():948597. PubMed ID: 36389713
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: A systematic evaluation and meta-analysis.
Lu Y; Zhang X; Ning J; Zhang M
Hum Vaccin Immunother; 2023 Dec; 19(1):2169531. PubMed ID: 36715018
[TBL] [Abstract][Full Text] [Related]
19. Advances and challenges of first-line immunotherapy for non-small cell lung cancer: A review.
Guo H; Zhang J; Qin C; Yan H; Luo X; Zhou H
Medicine (Baltimore); 2024 Jan; 103(3):e36861. PubMed ID: 38241591
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Chen R; Hou X; Yang L; Zhao D
Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]